Nowarta Biopharma
Private Company
Funding information not available
Overview
Nowarta Biopharma is a private, pre-revenue biotech founded in 2020, advancing a novel botanical drug candidate, Nowarta110, through clinical development. The company's lead program targets HPV-induced plantar warts, having demonstrated a 64.3% complete lesion clearance rate with zero serious adverse events in a Phase I/II study, with a Phase 3 trial planned for 2026. Nowarta is pursuing an ambitious pipeline expansion into cervical dysplasia (CIN 2,3), COVID-19, and skin cancers, leveraging regulatory designations like Fast Track, though its early-stage and broad focus present significant development and execution risks.
Technology Platform
Proprietary botanical composition (Nowarta110) with claimed broad-spectrum antiviral and anti-cancer activity, supported by patents and a reported strong non-clinical safety profile.
Opportunities
Risk Factors
Competitive Landscape
The plantar wart space has existing treatments but lacks a dominant, highly effective topical drug. The cervical dysplasia and oncology markets are highly competitive with advanced modalities, requiring Nowarta110 to demonstrate superior efficacy or safety. The COVID-19 antiviral market is already crowded.